EPAS1 and ischemic disease: By changing the conformation of side chains of amino acid residues at the interface of the HIF2α-ARNT dimer, the small molecule agonist can affect the stability of the dimer and regulate its transcriptional activity, providing a new target for the diagnosis and treatment of renal anemia and other ischemic diseases [33].